Cala Health, a San Mateo, CA-based non-invasive bioelectronic medicine company, raised $50M in funding.
The round was led by Vertex Growth Fund and Nexus NeuroTech Ventures. Existing investors participated in the round, including Action Potential, Johnson & Johnson, Lightstone, Lux, GV (Google Ventures), OSF Ventures, Ascension Ventures, TriVentures, Reimagined Ventures, Peak6 and Fiscus.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Deanna Harshbarger, Cala Health is a bioelectronic medicine company that is advancing wearable neuromodulation therapies that merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and a direct-to-home digital durable medical equipment (DME) platform. Its products are FDA-cleared, clinically validated noninvasive devices for the relief of hand tremors, allowing patients with essential tremor to return to the moments that matter.
New therapies are under development in neurology, cardiology, and psychiatry.
Cala’s kIQ System with TAPS™ Therapy is a non-invasive, FDA-cleared, wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The TAPS device is clinician-prescribed and clinically proven to safely and effectively reduce action hand tremors. The Cala kIQ device treats tremor by sensing each patient’s tremor signature and delivering individualized stimulation to the nerves on the wrist that then reach the brain to counteract tremor.
